TRASTUZUMAB INDUCED CARDIOTOXICITY IN PATIENTS WITH HER2+BREAST CANCER

被引：0
|
作者：
Santamaria Elena, Capilla [1 ]
Garcia Beatriz, Benitez [1 ]
Jose Antonio, Romero Garrido [1 ]
Aunon Pilar, Zamora [2 ]
Abad Gema, Casado [1 ]
del Valle Luis, Gonzalez [1 ]
Ambrosio Alicia, Herrero [1 ]
机构：
[1] Hosp Univ La Paz, Dept Pharm, Madrid, Spain
[2] Hosp Univ La Paz, Dept Oncol, Madrid, Spain
来源：
ATENCION FARMACEUTICA | 2013年 / 15卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Objective: To assess the incidence of trastuzumab induced cardiotoxicity in clinical practice. Method: A retrospective study was conducted on HER2+ breast cancer patients who started treatment with trastuzumab in 2008 and 2009, and were monitored for one year. Results: 67 patients were included. The cardiotoxicity incidence was 46.3% with a mean time of onset from 5.5 +/- 3.3 months. The most commonly criterion was the decline in LVEF (Left Ventricular Ejection Fraction) >10 points from baseline value (28.4%). 45.1% of the cases were symptomatic cardiotoxicity. A baseline LVEF of >67% was associated with cardiotoxicity (p < 0.05). Conclusions: The incidence of cardiotoxicity in clinical practice was higher than that obtained in different clinical trials. It is necessary to reach consensus between professionals to ensure the drug's safety without limiting benefit for the patient.
引用
收藏
页码：261 / 267
页数：7
相关论文
共 50 条
  • [1] Pruritus related to trastuzumab and pertuzumab in HER2+breast cancer patients
    Gu, Stephanie
    Dusza, Stephen
    Quigley, Elizabeth
    Haliasos, Helen
    Markova, Alina
    Marchetti, Michael
    Moy, Andrea P.
    Dang, Chau
    Modi, Shanu
    Lake, Diana
    Noor, Sarah
    Lacouture, Mario E.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 271 - 280
  • [2] Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+breast cancer
    Iwata, H.
    Yamamoto, N.
    Masuda, N.
    Bando, H.
    Kuroi, K.
    Ohno, S.
    Kasai, H.
    Morita, S.
    Sakurai, T.
    Toi, M.
    [J]. BREAST, 2015, 24 : S95 - S95
  • [3] Safety of trastuzumab in women with HER2+breast cancer.
    Nowsheen, Somaira
    Aziz, Khaled
    Park, Jae Yoon
    Villarraga, Hector R.
    Herrmann, Joerg
    Ruddy, Kathryn Jean
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] HER2+breast cancer treatment and cardiotoxicity: monitoring and management
    Jerusalem, Guy
    Lancellotti, Patrizio
    Kim, Sung-Bae
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (02) : 237 - 250
  • [5] Cardiotoxicity in HER2 positive breast cancer patients treated with trastuzumab
    Lopez, M.
    Minguito Carazo, C.
    Delgado Sillero, I.
    Rojas Piedra, M.
    Tavara Silva, B.
    Lopez-Gonzalez, A.
    Castanon Lopez, C.
    Nieto Mangudo, B.
    Pedraza Lorenzo, M.
    Rodriguez Sanchez, A.
    Diz Tain, P.
    De Sande Gonzalez, L. M.
    Medina Valdivieso, S.
    Lopez Gonzalez, L.
    Honrado Franco, E.
    Garcia-Palomo, A.
    Sanchez-Cousido, L. F.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S332 - S332
  • [6] Trastuzumab-Induced Tumor Microenvironment Changes in Early HER2+Breast Cancer
    Kennedy, Laura C.
    Alvarez, Rebeca
    Dintzis, Suzanne
    Gadi, Vijayakrishna K.
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [7] Trastuzumab-induced cardiotoxicity in Uruguayan HER2-positive breast cancer patients.
    Schiavone, Andrea
    Diaz, Mariana
    Camejo, Natalia
    Reborido, Natalia
    Vazquez, Horacio
    Parma, Gabriel
    Vazquez, Alvaro
    Castillo, Cecilia
    Krygier, Gabriel David
    Delgado, Lucia Beatriz
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [8] Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital
    Ayres, Lorena Rocha
    de Almeida Campos, Marilia Silveira
    Gozzo, Thais de Oliveira
    Martinez, Edson Zangiacomi
    Ungari, Andrea Queiroz
    de Andrade, Jurandyr Moreira
    Leira Pereira, Leonardo Regis
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (02) : 365 - 372
  • [9] Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital
    Lorena Rocha Ayres
    Marília Silveira de Almeida Campos
    Thais de Oliveira Gozzo
    Edson Zangiacomi Martinez
    Andrea Queiróz Ungari
    Jurandyr Moreira de Andrade
    Leonardo Régis Leira Pereira
    [J]. International Journal of Clinical Pharmacy, 2015, 37 : 365 - 372
  • [10] Trastuzumab in metastatic HER2+ breast cancer: cardiotoxicity
    [J]. Reactions Weekly, 2020, 1794 (1) : 12 - 12
12345